The most recent report by the National Health and Morbidity
Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with
consistent, unrelenting efforts by stakeholders and policymakers, the figures
for NCDs continue to climb.
MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in
the country and to obtain his thoughts on the ramifications of the findings.
On 18 July 2020, the Malaysian Endocrine and Metabolic Society (MEMS) collaborated with MIMS Education and was supported by Abbott Nutrition to bring the webinar entitled Taking A1ction Now to HCPs, including doctors and pharmacists. The webinar discussed the issues of type 2 diabetes mellitus (T2DM) patients being prone to severe COVID-19 infection and their difficulties in coping with nutrition aspects during the pandemic as well as the role of diabetes-specific nutrition in ensuring T2DM patients thrive during this challenging period.
Chronic heart failure (CHF) is a significant public health concern, affecting at least 26 million individuals worldwide.1 In this case study, Professor Dr Chee Kok Han and Dr Nur Asyikin share their clinical experience running the Heart Failure Frequent Flyer Programme – an initiative between HTAR and UMMC. The Programme enrols CHF patients who had been hospitalised for HF at least twice over the past 12 months and diagnosed with New York Heart Association (NYHA) class II–IV.2
CHF is a frequent cause of hospitalisation at HTAR – a total of 1,140 patients were admitted for CHF between April 2017 and April 2018, with a mean length of stay of 8.2 days. In addition to causing high mortality, hospitalisation for HF (HHF) also places a significant financial burden on patients and the healthcare system. Notably, frequent hospitalisation strongly predicts mortality among patients with CHF – approximately 93% of CHF patients treated at HTAR have recent histories of recurrent admission to the hospital for worsening HF.
The Heart Failure Frequent Flyer Programme was set up with the principal goal of reducing hospitalisation in patients with CHF to improve functional status, quality of life (QoL) and cost of care.The Programme is conducted via a holistic and multidisciplinary approach, incorporating a dedicated HF team (consisting of clinical specialists, clinical pharmacists, HF nurses, dietitian and cardiac rehabilitation team), pharmacist-led patient counselling sessions, as well as nurse-led telemonitoring and SOS walk-in services.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
In this fourth issue,
join us as we discover the unique biology Asians have with respect to diabetes.
Take a closer look at trials evaluating whether empagliflozin’s cardiovascular
and renal benefits – as analysed in Asians – are consistent with the overall
trial population, and how it addresses unmet needs.
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illness. On the first day, eminent local and internationalexperts weighed in on the treatment of major depressive disorder (MDD), including in the elderly and incases of coexisting anxiety.
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.